About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Researchers Identify Genetic Variation Behind Acute Myeloid Leukemia Treatment Success

by Bidita Debnath on February 28, 2013 at 11:48 AM
Font : A-A+

 Researchers Identify Genetic Variation Behind Acute Myeloid Leukemia Treatment Success

Researchers have identified genetic variations that may help signal which acute myeloid leukemia (AML) patients will benefit or not benefit from one of the newest antileukemic agents.

Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered for this study. Their study is published today in Clinical Cancer Research.

Advertisement

In the latest study, U of M researchers evaluated how inherited genetic polymorphisms in CD33, a protein that naturally occurs in most leukemia cells, could affect clinical outcomes of patients treated with an existing chemotherapy drug, gemtuzumab ozogamicin (GO), an immuno-conjugate between anti-CD33 antibody and a cytotoxin known as calicheamicin, which binds to CD33 on leukemic cells. As GO is internalized by leukemia cells, the cytotoxin is released, causing DNA damage and generating leukemic cell death.

In recent clinical trials GO has been shown to induce remission and improve survival in subset of patients with AML, however there is wide inter-patient variation in response.
Advertisement

Jatinder Lamba, Ph.D., and colleagues identified and evaluated three genetic variations of CD33 in two groups of patients with pediatric AML - one group that received the drug GO, and one group that did not. They found that specific genetic variation in CD33 that significantly affected the clinical outcome of AML patients who received GO based chemotherapy.

"Understanding how genetics play a role in how drugs work is extremely useful, particularly for a drug like GO which has shown a very heterogeneous response in AML patients," said Jatinder Lamba, Ph.D., the study's lead author and a researcher who holds appointments in both the College of Pharmacy and the Masonic Cancer Center, University of Minnesota. "Our latest findings lead us to believe that genetic variation in CD33 influences how AML patients' leukemic cell responds to GO."

AML is a cancer of the blood and bone marrow, and is the second most common form of leukemia in children. Though the most common type of treatment for AML is chemotherapy, Lamba says the disease remains hard to treat and newer, more effective therapies are needed.

"The overall goal of our study was to use genetic data to predict beneficial or adverse response to a specific drug, thus opening up opportunities to use this information for drug optimization to achieve maximum therapeutic efficacy and minimum toxicity. Our hope is that our research could serve as a marker of prognostic significance for clinicians to select the therapy that has the greatest odds of being effective for individual patients based on their CD33 genotype."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Turmeric: Magic Ingredient to Keep you Healthy in Winter
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia Genetics and Stem Cells Acute Lymphoblastic Leukemia Multiple Myeloma Bone Marrow Transplantation Hairy Cell Leukemia Christianson Syndrome Neutropenic Sepsis 

Recommended Reading
Improvement In Treatment for Acute Myeloid Leukemia Possible Due To Gene Discovery
Scientists have made a discovery involving mice and humans that could mean that people with acute .....
Researchers Discover New Target in Acute Myeloid Leukemia
A new pathway activated by FLT3 mutation has been identified by scientists. A...
‘Oncometabolite’ Linked to Onset of Acute Myeloid Leukemia
(TORONTO, July 4, 2012) - A team of international scientists led by principal investigator Dr. Tak ....
Gene FLT3 Valid Target in Acute Myeloid Leukemia Treatment
A group of American researchers have found that gene FLT3 can be a valid target in treating one of ....
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lympho...
Acute Myeloid Leukemia
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving leukem...
Bone Marrow Transplantation
Preferred Term is Hematopoietic stem cell transplantation. In this stem cell from bone marrow are in...
Christianson Syndrome
Christianson syndrome is a condition that occurs due to mutations (abnormal changes) in the gene SLC...
Chronic Myeloid Leukemia
Chronic myeloid Leukemia is one of the most common types of blood cancer. It is characterized by ex...
Hairy Cell Leukemia
Hairy cell leukemia (HCL) is a type of leukemia where there are increased numbers of abnormal B-lymp...
Leukemia
Encyclopedia section of medindia gives general information about Leukemia...
Multiple Myeloma
Multiple Myeloma caught public attention when model turned actress Lisa Ray, who worked in Deepa Meh...
Neutropenic Sepsis
Neutropenic sepsis is a potentially life-threatening condition when a patient with low neutrophil co...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use